LYEL

Conviction 38HealthcareScan · Mon, Aug 10, 2026

LYEL$14.32-2.65%

ResistanceSupportVol 14Insider sell

Vol MA14 224.73K

May 11May 28Jun 16Jul 6Jul 23Aug 10

Lyell Immunopharma, Inc.PHARMACEUTICAL PREPARATIONSwww.lyell.com ↗

Price14.32

Change-2.65%

Gap-0.54%

Rel volume4.57×

Avg volume202.39K

Avg $ vol2.75M

SMA 2013.39

SMA 5013.54

SMA 20020.53

Price vs 50+5.77%

Price vs 200-30.25%

MA stackmixed

50/200 cross—

Supertrendup · 11.72

RSI (14)55

MACD hist0.21

MACD crossbull · 7d

Stoch %K / %D59 / 62

ADX (14)22

+DI / −DI26 / 9

RSI divergence—

MACD divergence—

ATR %+7.24%

ADR %6.50%

52w high38.60

52w low10.57

From 52w high-62.90%

Above 52w low+35.48%

New 52w highNo

SqueezeOn · 4d

Bollinger width17.66%

%B0.89

Donchian pos58.90%

Donchian high15.63

Donchian low12.45

AVWAP (52w high)18.92

vs AVWAP high-24.33%

AVWAP (52w low)18.95

vs AVWAP low-24.43%

OBV trendDown

Chaikin MF (20)-0.19

Today vs 20d4.57×

Avg vol (14d)224.73K

Avg vol (20d)202.39K

Avg $ vol (20d)2.75M

Market cap350.91M

RS 3m (vs SPY)-32.37%

RS 6m (vs SPY)-49.14%

RS line new highNo

Trend template2/8

Technical rank29.6

1 week+11.27%

1 month-4.60%

3 months-25.92%

6 months-36.94%

1 year+26.50%

YTD-50.59%

P/E-1.28

P/B1.50

P/S—

P/FCF-2.33

EPS-16.06

Div yield—

ROE-117.38%

ROA-88.20%

Debt/Eq—

Current5.36

EV/EBITDA-1.08

Gross margin—

Net margin—

Rev growth-40.98%

EPS growth19.98%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value277.93M

Revenue4K

Net income-44.76M

Gross profit—

Free cash flow-150.8M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out23.33M

Employees161

ListedThu, Jun 17, 2021

Free float6.6M

Float %31.1%

Short interest1.22M

Days to cover6.7d

Short volume61.1%

Squeeze score91 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction38 / 100

Pattern quality—

Tech rank29.6 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance16.21

Support11.57

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in LYEL

All disclosures →

No recent disclosed trades by Congress in LYEL. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in LYEL · 2 buys · 4 sells

Insider	Side	Shares	Value	Traded	Filed
Innovative Cellular Therapeutics Holdings Ltd 10% owner · Common Stock · 2026-07-27	Dispose	38.5K	—	2026-07-27	2026-07-27
Innovative Cellular Therapeutics Holdings Ltd 10% owner · Common Stock · 2026-07-27	Dispose	44K	—	2026-07-27	2026-07-27
Innovative Cellular Therapeutics Holdings Ltd 10% owner · Common Stock · 2026-07-16	Sell	10	$137	2026-07-16	2026-07-17
Innovative Cellular Therapeutics Holdings Ltd 10% owner · Common Stock · 2026-06-15	Dispose	66.5K	—	2026-06-15	2026-06-18
BRAWLEY OTIS W Director · Option (right to buy) · 2026-06-10	Grant	9.25K	—	2026-06-10	2026-06-12
Bachleda Mark Director · Option (right to buy) · 2026-06-10	Grant	9.25K	—	2026-06-10	2026-06-12

SEC filings

EDGAR filings in LYEL · 5 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.